CORAL GABLES, FL / ACCESSWIRE / March 7, 2019 / The healthcare stock market has gotten off to an impressive start in the first few months of 2019, as companies in the healthcare sector work to pioneer innovative drug treatment options and care solutions for the millions of patients in need. On a near daily basis, headlines detailing a company's new drug approval or a technological breakthrough emerge, indicating to potential investors that they could benefit from paying attention to the healthcare sector. Premier Health Group (OTC:PHGRF) (CSE:PHGI), GTx Inc (GTXI), Co-Diagnostics Inc (CODX), and Novavax Inc (NASDAQ:NVAX) represent 4 healthcare companies heating up on Thursday.
Premier Health Group (OTC:PHGRF) (CSE:PHGI) is a focused on developing innovative approaches that combine human skill-based expertise to maintain a healthcare framework which supports the Company's active patient network of over 100,000 patients, with plans to grow that number both domestically and globally.
Premier Health Group (OTC:PHGRF) (CSE:PHGI) announced earlier this week that they are working with NexTech AR Solutions to explore bringing augmented reality technologies to its patient-centric healthcare app. Premier Health will be working with NexTech to develop educational tools for healthcare professionals and patients alike - some of which will be created and commercialized content for third parties. Utilizing AR as a learning tool in training healthcare professionals creates a highly engaging and immersive educational experience which aids in retention and how well complex concepts can be grasped.
Following the announcement, Dr. Essam Hamza, CEO of Premier Health Group (OTC:PHGRF) (CSE:PHGI), stated, "at Premier Health we pride ourselves in being at the forefront of changes in healthcare, so we are thrilled to be a part of the future of healthcare by enabling state of the art technological advancements to our patient-centric telemedicine app. AR has the potential to revolutionize both the access to data and the delivery of healthcare. The technology will help doctors and patients alike - doctors will have access to the latest and most relevant information about their patients while patients can use AR for self-education and improving the quality of treatment they receive."
GTx Inc (GTXI) and Oncternal Therapeutics Inc, a privately held clinical-stage biotechnology company, today jointly announced that they have entered into a definitive merger agreement under which the stockholders of Oncternal would become the majority owners of GTx's outstanding common stock. Following the closing of the agreement, the proposed merger will create a publicly-traded, clinical-stage oncology company.
Following the announcement, Robert J. Wills, Executive Chairman of GTx, said, "following a thorough review of strategic alternatives, we have determined that a reverse merger with Oncternal will enable GTx investors to participate in Oncternal's broader pipeline of oncology opportunities, including product candidates designed to address rare disease indications, and enable the continued development of our first-in-class SARD technology by a company whose leadership has deep experience in developing oncology medicines."
Co-Diagnostics Inc (CODX), a molecular diagnostics company with a platform for the development of molecular diagnostics tests, today annoyed that its Logix Smart™ ZDC Test has obtained CE mark regulatory clearance to be sold as an in vitro diagnostic for the diagnosis of Zika, dengue, and chikungunya in accepting markets, and is now available for purchase from the Company's Utah-based ISO-13485 facility.
Dwight Egan, CEO of Co-Diagnostics, stated, "receiving the CE mark for our CoPrimer™-based multiplex ZDC assay is the capstone of the design, development, validation, and regulatory approval process, which was completed from start to finish in under 6 months. This highly-specific diagnostic for three harmful diseases at once is possible due to our patented CoPrimer design platform enabling a massive reduction in false positives, which is especially important - but notoriously more difficult - in multiplexed assays of related pathogens.
Novavax Inc (NVAX) announced results from Prepare™, a global Phase 3 clinical trial using ResVax, an aluminum adjuvanted respiratory syncytial virus (RSV) fusion (F) protein recombinant nanoparticle vaccine at the tail-end of last month. Per the details of the announcement, ResVax is being developed to protect infants via maternal immunization against RSV disease.
Stanley Erck, President, and CEO of Novavax commented, "the potential to prevent these most serious outcomes during infants' most vulnerable months of life could have a profound impact upon the global burden of RSV disease. Our next steps include meeting with U.S. and European regulators to review these data and to discuss the path forward for licensure. We wish to acknowledge and thank the investigators, the Novavax team and the many mothers and their families around the world that participated in this historic trial, bringing the world one step closer to an RSV vaccine."
What Is Stock Price (StockPrice.com)?
Stock Price is defined as the price of a single share of a number of saleable stocks of a public company. A stock price is the highest amount an investor or trader is willing to pay for the stock, or the lowest amount that it can be bought for.
StockPrice.com was created for everyone that wants the latest stock quotes, stock charts, company news, and the best financial content.
At Stock Price (StockPrice.com), you get free stock quotes, up-to-date news, international market data, social interaction and the best financial content that will help you manage your financial life.
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. JSG Communications, LLC which owns www.StockPrice.com is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release.
JSG Communications, LLC, which owns www.StockPrice.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. JSG Communications, LLC, which owns www.StockPrice.com, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two.
Pursuant to an agreement between an affiliate of MAPH Enterprises, LLC (owners of MarijuanaStocks.com), MIDAM VENTURES, LLC and Premier Health Group Inc. Midam was hired for a period from 10/1/2018 - 4/1/2019 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. We were paid $300,000 CASH for & were paid "500,000" shares of restricted common shares (as of 1/2/2019). Midam has been compensated an additional $100,000 by Premier Health Group to extend the period of coverage to May 1, 2019. We own zero shares of Premier Health Group Inc., which we purchased in the open market. Once the (6) Six-month restriction is complete on 4/1/2019 we plan to sell the "500,000" shares of Premier Health Group Inc. that we hold currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Please click here for full disclaimer.
View source version on accesswire.com: